PURPOSE: Radical prostatectomy and brachytherapy are widely used treatments for favorable risk prostate cancer. We estimated the risk of prostate cancer specific mortality following radical prostatectomy or brachytherapy in men with low or intermediate risk prostate cancer using prospectively collected data. MATERIALS AND METHODS: The study cohort comprised 5,760 men with low risk prostate cancer (prostate specific antigen 10 ng/ml or less, clinical category T1c or 2a and Gleason score 6 or less), and 3,079 with intermediate risk prostate cancer (prostate specific antigen 10 to 20 ng/ml, clinical category T2b or T2c, or Gleason score 7). Competing risks multivariable regression was performed to assess the risk of prostate cancer specific mortality after radical prostatectomy or brachytherapy, adjusting for age, year of treatment, cardiovascular comorbidity and known prostate cancer prognostic factors. RESULTS: After a median followup of 4.2 years (IQR 2.0-7.4) for low risk and 4.8 years (IQR 2.2-8.1) for intermediate risk men, there was no significant difference in the risk of prostate cancer specific mortality among low risk (adjusted hazard ratio 1.62, 95% CI 0.59-4.45, p = 0.35) or intermediate risk men (AHR 2.30, 95% CI 0.95-5.58, p = 0.07) treated with brachytherapy compared with radical prostatectomy. The only factor associated with an increased risk of prostate cancer specific mortality (AHR 1.05, 95% CI 1.01-1.10, p = 0.03) was increasing age at treatment in intermediate risk men. CONCLUSIONS: The risk of prostate cancer specific mortality in men with low or intermediate risk prostate cancer was not significantly different following radical prostatectomy vs brachytherapy.
PURPOSE: Radical prostatectomy and brachytherapy are widely used treatments for favorable risk prostate cancer. We estimated the risk of prostate cancer specific mortality following radical prostatectomy or brachytherapy in men with low or intermediate risk prostate cancer using prospectively collected data. MATERIALS AND METHODS: The study cohort comprised 5,760 men with low risk prostate cancer (prostate specific antigen 10 ng/ml or less, clinical category T1c or 2a and Gleason score 6 or less), and 3,079 with intermediate risk prostate cancer (prostate specific antigen 10 to 20 ng/ml, clinical category T2b or T2c, or Gleason score 7). Competing risks multivariable regression was performed to assess the risk of prostate cancer specific mortality after radical prostatectomy or brachytherapy, adjusting for age, year of treatment, cardiovascular comorbidity and known prostate cancer prognostic factors. RESULTS: After a median followup of 4.2 years (IQR 2.0-7.4) for low risk and 4.8 years (IQR 2.2-8.1) for intermediate risk men, there was no significant difference in the risk of prostate cancer specific mortality among low risk (adjusted hazard ratio 1.62, 95% CI 0.59-4.45, p = 0.35) or intermediate risk men (AHR 2.30, 95% CI 0.95-5.58, p = 0.07) treated with brachytherapy compared with radical prostatectomy. The only factor associated with an increased risk of prostate cancer specific mortality (AHR 1.05, 95% CI 1.01-1.10, p = 0.03) was increasing age at treatment in intermediate risk men. CONCLUSIONS: The risk of prostate cancer specific mortality in men with low or intermediate risk prostate cancer was not significantly different following radical prostatectomy vs brachytherapy.
Authors: George Rodrigues; Xiaomei Yao; D Andrew Loblaw; Michael Brundage; Joseph L Chin Journal: Can Urol Assoc J Date: 2013 May-Jun Impact factor: 1.862
Authors: Jouhyun Jeon; Ekaterina Olkhov-Mitsel; Honglei Xie; Cindy Q Yao; Fang Zhao; Sahar Jahangiri; Carmelle Cuizon; Seville Scarcello; Renu Jeyapala; John D Watson; Michael Fraser; Jessica Ray; Kristina Commisso; Andrew Loblaw; Neil E Fleshner; Robert G Bristow; Michelle Downes; Danny Vesprini; Stanley Liu; Bharati Bapat; Paul C Boutros Journal: J Natl Cancer Inst Date: 2020-03-01 Impact factor: 13.506
Authors: Gabriele Cozzi; Gennaro Musi; Roberto Bianchi; Danilo Bottero; Antonio Brescia; Antonio Cioffi; Giovanni Cordima; Maurizio Delor; Ettore Di Trapani; Matteo Ferro; Deliu Victor Matei; Andrea Russo; Francesco Alessandro Mistretta; Ottavio De Cobelli Journal: Ther Adv Urol Date: 2017-10-09
Authors: Trevor J Royce; Ming-Hui Chen; Jing Wu; Marian Loffredo; Andrew A Renshaw; Philip W Kantoff; Anthony V D'Amico Journal: JAMA Oncol Date: 2017-05-01 Impact factor: 31.777
Authors: Kamran A Ahmed; Brian J Davis; Lance A Mynderse; Jeffrey M Slezak; Eric J Bergstralh; Torrence M Wilson; C Richard Choo Journal: Radiat Oncol Date: 2014-07-29 Impact factor: 3.481
Authors: John M Lacy; William A Wilson; Raevti Bole; Li Chen; Ali S Meigooni; Randall G Rowland; William H St Clair Journal: Prostate Cancer Date: 2016-03-22